Form 13-F position report

UNUM THERAPEUTICS INC

Reported by VANGUARD GROUP INC

COGT CUSIP 19240Q201 Manager CIK 0000102909

Reported 5,714,405 shares, up 454,526 (8.6%) from the prior quarter.

Reported value 39.2%; share count 8.6% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2024
Shares 5,714,405 Quarter-end amount reported
Reported value $61,715,574 Fair value at quarter end
Consecutive quarters held 16 Through Q3 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 18738000
2021-06-30 13031000
2021-09-30 13431000
2021-12-31 14180000
2022-03-31 12306000
2022-06-30 23324000
2022-09-30 47502000
2022-12-31 40064556
2023-03-31 38156234
2023-06-30 52529593
2023-09-30 42639782
2023-12-31 26663771
2024-03-31 38745537
2024-06-30 44340781
2024-09-30 61715574
2024-12-31 47840364
2025-03-31 36289444
2025-06-30 46834788
2025-09-30 111400026
2025-12-31 408988860

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for UNUM THERAPEUTICS INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 11,514,326 +3,756,664 (48.4%) < 0.01% $408,988,860 2026-01-29
Q3 2025 Added 7,757,662 +1,234,711 (18.9%) < 0.01% $111,400,026 2025-11-07
Q2 2025 Added 6,522,951 +464,613 (7.7%) < 0.01% $46,834,788 2025-08-11
Q1 2025 Reduced 6,058,338 -75,042 (-1.2%) < 0.01% $36,289,444 2025-05-09
Q4 2024 Added 6,133,380 +418,975 (7.3%) < 0.01% $47,840,364 2025-02-11
Q3 2024 Added 5,714,405 +454,526 (8.6%) < 0.01% $61,715,574 2024-11-13
Q2 2024 Reduced 5,259,879 -505,826 (-8.8%) < 0.01% $44,340,781 2024-08-13
Q1 2024 Added 5,765,705 +1,231,050 (27.1%) < 0.01% $38,745,537 2024-05-10
Q4 2023 Added 4,534,655 +161,344 (3.7%) < 0.01% $26,663,771 2024-02-14
Q3 2023 Reduced 4,373,311 -63,310 (-1.4%) < 0.01% $42,639,782 2023-11-14
Q2 2023 Added 4,436,621 +900,362 (25.5%) < 0.01% $52,529,593 2023-08-14
Q1 2023 Added 3,536,259 +70,467 (2.0%) < 0.01% $38,156,234 2023-05-15
Q4 2022 Added 3,465,792 +282,022 (8.9%) < 0.01% $40,064,556 2023-02-10
Q3 2022 Added 3,183,770 +597,966 (23.1%) < 0.01% $47,502,000 2022-11-14
Q2 2022 Added 2,585,804 +942,835 (57.4%) < 0.01% $23,324,000 2022-08-12
Q1 2022 Reduced 1,642,969 -9,764 (-0.6%) < 0.01% $12,306,000 2022-05-13
Q4 2021 Added 1,652,733 +55,617 (3.5%) < 0.01% $14,180,000 2022-02-14
Q3 2021 Reduced 1,597,116 -9,673 (-0.6%) < 0.01% $13,431,000 2021-11-12
Q2 2021 Reduced 1,606,789 -527,454 (-24.7%) < 0.01% $13,031,000 2021-08-13
Q1 2021 Added 2,134,243 +1,275,787 (148.6%) < 0.01% $18,738,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

181 managers reported UNUM THERAPEUTICS INC for Q3 2024.

Managers reporting UNUM THERAPEUTICS INC in Q3 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Point72 Asset Management L P Unchanged 10,470,398 0 0.29% $113,080,298 16 qtrs
Kynam Capital Management LP Reduced 9,239,731 -20,654 7.65% $99,789,095 12 qtrs
FMR LLC Added 8,319,411 +625,743 < 0.01% $89,849,641 12 qtrs
BlackRock Inc New 7,991,587 +7,991,587 < 0.01% $86,309,140 1 qtr
COMMODORE CAPITAL LP Reduced 7,539,930 -2,198,070 5.09% $81,431,244 16 qtrs
TCG Crossover Management LLC Unchanged 6,964,375 0 6.37% $75,215,250 12 qtrs
Fairmount Funds Management LLC Unchanged 6,225,641 0 5.45% $67,236,923 16 qtrs
VANGUARD GROUP INC This report Added 5,714,405 +454,526 < 0.01% $61,715,574 16 qtrs
VR Adviser LLC Unchanged 5,684,167 0 3.22% $61,389,004 16 qtrs
Paradigm Biocapital Advisors LP Added 4,609,762 +985,420 1.68% $49,785,430 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2024
Filed
November 13, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
159,043
None
5,555,362

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.